JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by VUKOVICH, R. A.
Right arrow Articles by COON, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VUKOVICH, R. A.
Right arrow Articles by COON, J. M.
Journal of Pharmacology And Experimental Therapeutics, Vol. 178, Issue 2, 395-401, 1971
Copyright © 1971 by American Society for Pharmacology and Experimental Therapeutics


THE EFFECT OF CHLORPROMAZINE ON THE TOXICITY AND BIOTRANSFORMATION OF PARATHION IN MICE

R. A. VUKOVICH 1, A. J. TRIOLO 1, and J. M. COON 1

1 Department of Pharmacology, Jefferson Medical College, Philadelphia, Pennsylvania

The toxicity of oral parathion and paraoxon in mice was increased by 30 mg/kg of chlorpromazine (CPZ) injected i.p. one or six hours previously. The toxicity of these agents was reduced, however, when CPZ was administered one day previously. Hepatic microsomal and 900 x g supernatant fractions obtained from mice 24 hours after CPZ treatment converted more parathion to the active cholinesterase inhibitor, paraoxon, than did control preparations. One hour after CPZ this "activation" reaction was significantly inhibited. The detoxication of paraoxon by these liver fractions from mice given CPZ either one hour or one day earlier was not affected. The one-day pretreatment with CPZ had no effect on the inhibition of whole blood, red blood cell or plasma cholinesterase, but it reduced the inhibition of brain cholinesterase by parathion and paraoxon. This CPZ treatment did not affect the plasma levels of parathion, but the brain levels of parathion were significantly lowered. The protection by CPZ against the inhibition of brain cholinesterase by paraoxon suggests that paraoxon levels in brain are also lowered by CPZ. These findings are consistent with the conclusion that the protective effect of CPZ against the toxicity of parathion and paraoxon is due to decreased amounts of these agents in the brain.

Submitted on October 29, 1970
Accepted on April 4, 1971







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1971 by the American Society for Pharmacology and Experimental Therapeutics.